Literature DB >> 29147619

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Morten Orebo Holmström1,2, Hans Carl Hasselbalch1, Mads Hald Andersen2,3.   

Abstract

Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.

Entities:  

Keywords:  CD4 T-cells; Hematological cancer; JAK2; calreticulin; neoantigens

Year:  2017        PMID： 29147619      PMCID： PMC5674967          DOI： 10.1080/2162402X.2017.1358334

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

2.  The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Authors:  M O Holmström; M D Hjortsø; S M Ahmad; Ö Met; E Martinenaite; C Riley; P Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2016-10-20       Impact factor: 11.528

3.  The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Authors:  M O Holmström; C H Riley; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

4.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 6.  Anti-regulatory T cells.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-27       Impact factor: 9.623

Review 7.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

8.  The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Authors:  M O Holmström; E Martinenaite; S M Ahmad; Ö Met; C Friese; L Kjær; C H Riley; P Thor Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2017-07-05       Impact factor: 11.528

Review 9.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
  10 in total
  4 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

2.  Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.

Authors:  Mia Aaboe Jørgensen; Morten Orebo Holmström; Evelina Martinenaite; Caroline Hasselbalch Riley; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

Review 3.  Immunotherapy in Myeloproliferative Diseases.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

Review 4.  Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar-Cases Series and a Review of the Literature.

Authors:  Marta Sobas; Maria Podolak-Dawidziak; Krzysztof Lewandowski; Michał Bator; Tomasz Wróbel
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.